Memorial Sloan Kettering Cancer CenterNew York, New York, United States
Disclosure information not submitted.
Paper 45 - A PHASE II STUDY OF PALBOCICLIB COMBINED WITH THE PD-1 INHIBITOR RETIFANLIMAB IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA
Friday, November 15, 20249:00 AM – 10:00 AM PST
Paper 89 - PERIPHERAL BLOOD T CELL PHENOTYPE AND TUMOR MICROENVIRONMENT SUBTYPE ARE INDEPENDENTLY ASSOCIATED WITH IMMUNE CHECKPOINT BLOCKADE OUTCOMES IN SARCOMAS
Saturday, November 16, 202410:30 AM – 12:00 PM PST
